Login to Your Account



Pancreatic Cancer, Too

Onconova Gets up to $565M in Phase III MDS Baxter Deal

By Randy Osborne
BioWorld Today Contributing Writer

Thursday, September 20, 2012

Onconova Therapeutics Inc.'s deal with Baxter International Inc. for European rights to rigosertib for myelodysplastic syndromes (MDS) and pancreatic cancer, worth up to $565 million, tops off a string of agreements over the past few years that leaves the company with full U.S. ownership of the late-stage compound.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription